# Use of Tocofersolan (Vedrop®) to Prevent or Treat Refractive Vitamin E Deficiency in Infants and Children

> **NCT03582384** · PHASE2 · WITHDRAWN · sponsor: **Boston Children's Hospital**

## Conditions studied

- Short Bowel Syndrome
- Vitamin E Deficiency

## Interventions

- **DRUG:** Tocofersolan

## Key facts

- **NCT ID:** NCT03582384
- **Lead sponsor:** Boston Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-12
- **Primary completion:** 2022-01
- **Final completion:** 2023-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study never started
- **Last updated:** 2020-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03582384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03582384, "Use of Tocofersolan (Vedrop®) to Prevent or Treat Refractive Vitamin E Deficiency in Infants and Children". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03582384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*